They joined us!
Date of creation: 31/07/2025
Number of employees: 4
Locations / Sites of operation: Lyon, 69006 et Besançon 25000
Field of activity (biotech/medtech/digital healthtech): Biotech
Who are they?
Oragen Therapeutics is a preclinical-stage biotechnology company developing an innovative oral nucleic acid delivery platform. Its initial focus is on inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), a major unmet medical need representing a market opportunity exceeding $30 billion annually.
Its proprietary technology enables the oral administration of therapeutic RNAs and their targeted release within inflamed intestinal tissues, delivering enhanced therapeutic efficacy, reduced systemic side effects, and improved patient adherence.
Its lead candidate, ORA-251, has demonstrated strong efficacy in preclinical models. Leveraging the precision and potency of nucleic acid–based therapies, Oragen Therapeutics aims to transform the treatment paradigm for intestinal diseases.
Why did they join Lyonbiopole?
Joining Lyonbiopole represents a strategic opportunity to position Oragen Therapeutics within an ecosystem recognized for its expertise in biotechnology and healthcare innovation. Lyonbiopôle fosters close interactions between biotechnology companies, researchers, and industrial partners, providing an optimal environment to accelerate the development of breakthrough therapeutic solutions.
Henri PIERRE
CEO & Co-Founder